ArticlePolymer science & technology (Washington, D.C.)2025
Immunologically Effective Chiral Polymers to Potentiate Anti-Cancer Immune Responses.
Article in Polymer science & technology (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Increasing hydrophobicity in poly(amino acid) adjuvants elicits potent and durable anti-tumor immunityBioactive materials · 2027Article
- Feasibility of Polylactic Acid-Polycaprolactone-Blended Microspheres in Transarterial Embolization Therapy.ACS omega · 2026Article
- Novel Composite Conduits for Long-Distance Peripheral Nerve Repair.Polymer science & technology (Washington, D.C.) · 2026Article
- A Hydrogen-Releasing Nanozyme Engineers a Mitochondrial ROS Amplifier for Self-Sustaining Catalytic Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Spatiotemporal activation of unfolded protein response by combined sonodynamic therapy and proteasome inhibition with bortezomib-conjugated TiN nanoparticles.Bioactive materials · 2026Article
- Engineered artificial antigen-presenting cells for tumor immunotherapy: Design strategies, clinical applications, and translational challenges.Materials today. Bio · 2026Review
- Biomimetic LHRH-targeted nanogels for spatiotemporal-enhanced chemo-dynamic therapy of cancer.Journal of nanobiotechnology · 2026Article
- Peptide-Incorporated Biomaterials Promote Regeneration of Peripheral Nerve Injuries.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune imbalance is a critical factor in the occurrence and progression of cancers because it disrupts the immune system's ability to detect and eliminate abnormal cells. Restoring immune balance and reactivating immune cells remain major challenges in cancer immunotherapy. Current immunoregulatory strategies, such as immune checkpoint blockade, adoptive cell therapy, and therapeutic vaccines, aim to influence key immune cells, such as T cells, dendritic cells, and macrophages, to boost anti-cancer responses. However, conventional material design in immunotherapy usually emphasizes chemical composition and physical morphology, while neglecting the critical role of stereochemistry in immune cell recognition and activation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.